616
Project, a project providing an effi cient tool to identify disease causing genes. The
Coriell Institute maintains contracts from the NIGMS and the National Institute of
Aging (NIA) to establish and maintain what has become one of the largest cell
repositories for the study of genetic and aging-related diseases.
Delaware Valley Personalized Medicine Project
The Delaware Valley Personalized Medicine Project (DVPMP) was established in
2007 with a goal of genotyping up to 100,000 patient volunteers for studies of the
use of genetic risk factors in patient care. At the time of its launch, DVPMP enrolled
10,000 participants for the project over the next 3 years and eventually plans to
reach 100,000 participants. Partners in the DVPMP include the Fox Chase Cancer
Center, Cooper University Hospital, and Virtual Health. In 2008, Coriell Institute
for Medical Research (see preceding section) started partnership with Cooper
University Hospital, which is the core clinical campus for the Robert Wood Johnson
Medical School in Camden, as part of the DVPMP. The collaborators intend to
enroll 2,000 Cooper employees and their families in the project.
Duke University Medical Center and Genomic Medicine
The Center for the Advancement of Genomics (TCAG) and Duke University
Medical Center (DUMC) started collaboration in 2003 to create the fi rst fully-
integrated, comprehensive practice of genomic-based prospective medicine. DUMC
and TCAG generated predictive and prognostic data on specifi c diseases to aid both
doctors and patients in the earlier detection and better treatment of these illnesses.
The activities included focused research in genomic predictors of diseases; the
design of future clinical practice models including personalized health planning;
and strategies to tackle ethical and legal issues. Initially funded internally by both
organizations, TCAG and DUMC sought outside funding through government
grants, foundations and philanthropic donations. This genomic-based medicine col-
laboration had several goals including creation of a futuristic personalized health
plan and medical record including genomic information to predict health risks and
outcomes from therapy.
By end of 2014, DUMC’s Institute for Genome Sciences and Policy (IGSP), was
broken down and restructured into three separate units that include: (1) a translation-
focused Center for Applied Genomics and Precision Medicine; (2) a core facility
tentatively named the Center for Genomic and Computational Biology; and (3)
Duke Science and Society, a free-standing policy and ethics institute that will
address a broad range of scientifi c issues. The facilities and staff from IGSP’s core
20 Development of Personalized Medicine